Comfort Systems USA Inc vs Organon & Co. Common Stock — how do they compare? Comfort Systems USA Inc trades at $1,495.05 (market cap $57.25B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Comfort Systems USA Inc is far larger — about 15.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 42 Days and Organon & Co. Common Stock for 0 Days on average.
| FIX | OGN | |
|---|---|---|
Market Cap | $57.25B | $3.62B |
Volume | 459,246 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $2.07K | $13.81 |
52-Week Low | $790.72 | $5.70 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | $55.72B | $11.04B |
Dividend Yield | 0.22% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,626.64, down 0.7% with bearish technical signals but strong fundamentals. The company demonstrates robust earnings momentum with three consecutive quarterly beats and impressive profitability metrics including 55.29% ROE. Recent acquisition of Hunt Electric expands Western electrical scale with $250M in annualized revenue. Technical indicators show bearish momentum with support at $1,611 and resistance at $1,687.
Outlook remains positive with analyst consensus price target of $2,080 representing 28% upside potential. Key opportunities include data center infrastructure demand and modular expansion, while risks involve project execution challenges and market volatility. The stock offers growth exposure to essential AI infrastructure services with strong institutional backing.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →